A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 23, 2017

Primary Completion Date

May 16, 2019

Study Completion Date

December 31, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Leuprolide Acetate

a GnRH agonist

DRUG

Prednisone

Prednisone is a corticosteroid

DRUG

Docetaxel

Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.

DRUG

Apalutamide

The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER